Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
Healthcare
$7.04 +0.99%
+$0.09 today
- Market cap
- $590.04M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
52W Low $1.94High $11.61
Volume 1.13M
Average 1.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$23.93M
FY 2025 · Annual
Investing Cash Flow
-$7.21M
FY 2025 · Annual
Financing Cash Flow
$107.39M
FY 2025 · Annual
+573.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.38M) | (8.23M) | (15.6M) | (21.61M) | (29.44M) |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 218.98K | 624.07K | 2.57M | 3.02M | 2.44M |
| Change in Working Capital | (391.04K) | 195.21K | 1.65M | 3.97M | 2.7M |
| Accounts Receivables | 97.67K | (236.38K) | (893.4K) | (971.53K) | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (106.06K) | 1.13M | 2.43M | 4.4M | 1.03M |
| Other Working Capital | (382.64K) | (700.15K) | 111.84K | 537.2K | (384.74K) |
| Other Non-Cash Items | 22.96M | 0 | 0 | 2.94M | 0 |
| Operating Cash Flow | (1.59M) | (7.41M) | (11.37M) | (14.6M) | (23.93M) |
| Capital Expenditures | (802) | 3 | (52.09K) | (1.18M) | (732.93K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (6.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (802) | 0 | (52.09K) | (1.18M) | (7.21M) |
| Debt Repayment | 200K | (50K) | 0 | 0 | 0 |
| Common Stock Issued | 18.65M | 3.39M | 15.7M | 15.95M | 107.39M |
| Common Stock Repurchased | 0 | (99.96K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (6.72K) | (232K) | 0 | 0 |
| Financing Cash Flow | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Effect of Forex Changes | (5.43K) | (31.52K) | 33.09K | (3.62K) | 3.84K |
| Net Change in Cash | 17.25M | (4.21M) | 4.07M | 172.16K | 76.25M |
| Free Cash Flow | (1.59M) | (7.41M) | (11.42M) | (15.77M) | (24.66M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$29.4M
+ D&A$364.5K
+ Stock-Based Comp$2.4M
+ Deferred Tax$0
+ Working Capital$2.7M
+ Other Non-Cash$0
= Operating Cash Flow-$23.9M
- Capex-$732.9K
= Free Cash Flow-$24.7M
Analysis
FY2025 free cash flow is -$24.7M. FCF conversion is 83.8% of net income. Operating cash flow was -$23.9M, with capex of -$732.9K. The largest bridge item is Working Capital at $2.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 424B5 | 424B5 filing | Sep 29, 2026 |
Does IMMX generate free cash flow?
Immix Biopharma, Inc. (IMMX) generated -$24.66M of free cash flow in fiscal 2025.
How much operating cash flow does IMMX produce?
Operating cash flow was -$23.93M, before capital expenditures of $732,925.00.
Continue the stock analysis
Jump to another research area for this company.